Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes

Area of Science:

• Endocrinology
• Metabolic Diseases
• Diabetes Mellitus Research

Background:

• Glycated hemoglobin A1c (A1C) is the traditional standard for assessing glycemic control in type 2 diabetes.
• A1C does not reflect blood glucose fluctuations, known as glycemic variability (GV).
• GV is increasingly recognized for its clinical relevance, impacting quality of life and treatment efficacy.

Purpose of the Study:

• To highlight the importance of glycemic variability (GV) in type 2 diabetes management.
• To discuss the relationship between A1C, GV, hyperglycemia, and hypoglycemia.
• To address the challenges in measuring and interpreting GV in clinical practice.

Main Methods:

• Review of current understanding of glycemic variability (GV) in type 2 diabetes.
• Analysis of the association between GV, A1C, and patient outcomes.
• Discussion of various metrics used to measure GV in clinical trials.

Main Results:

• Glycemic variability (GV) is linked to both hyperglycemia and hypoglycemia.
• GV has been associated with a reduced quality of life for patients with type 2 diabetes.
• Treatments targeting multiple mechanisms are most effective for controlling A1C and reducing GV.

Conclusions:

• Optimal type 2 diabetes management requires consideration of both A1C and glycemic variability (GV).
• The lack of a standardized GV metric complicates treatment choices.
• Further research is needed to establish a gold standard for GV measurement.